LMNA-related dilated cardiomyopathy (LMNA-DCM) is a severe and inherited disease caused by mutations in the LMNA gene. This gene provides instructions for making proteins called lamins (Lamins A/C), which help maintain the structure of the cell nucleus and play an important role in regulating chromatin organization, gene expression, and cytoskeletal organization by interacting with numerous other proteins. There is no effective treatment for LMNA-DCM because we do not fully understand the disease’s underlying mechanisms. Therefore, the proposed PRIORITY (cardio-laminoPathy: fRom pathomechanIsms tO peRsonalIzed TherapY) network aims to fill this knowledge gap and develop personalized, disease-modifying therapies.
Aims of PRIORITY
PRIORITY has three main Aims. Aim 1 investigates the clinical and genetic signs associated with LMNA-DCM, identifying factors to understand what factors affect the severity and progression of the disease. Aim 2 pursues the underlying disease mechanism(s) contributing to LMNA-related DCM, uncovering the complex cellular and molecular processes underlying the pathogenesis and disease progression using state-of-the-art technologies. Aim 3 develops mechanism-based therapies for LMNA-related DCM by leveraging existing concepts and novel findings from Aim 2, potentially offering personalized therapeutic options for LMNA-DCM patients.
Network
Our team is composed of internationally renowned experts from prestigious European institutions (Sorbonne Université-Inserm, Amsterdam University, Maastricht University, University of Zurich, Paris-Cité University) and the USA (Duke, Cornell, and Stanford), along with early career investigators. We have partnered with LMNA Cardiac Diseases Network, a patient-led foundation, to ensure a patient-centered approach and to address the needs of those affected by LMNA-DCM.
Company Details
- Address
- The Needs Of Those Affected By Lmna-Dcm.
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- http://lmna-priority.org
- Competitors
- Inthera, Korea Institute for Advancement of Technology (KIAT), 5th International Meeting on Laminopathies, KHIDI USA, LEDUCQ FOUNDATION FOR CARDIOVASCULAR RESEARCH, Cardiovascular Research Institute Maastricht (CARIM), Orthopedie UMC Utrecht, BactiVac, Cancer Research UMC Utrecht, Osong Medical Innovation Foundation.
Lmna Priority (Leducq Foundation) Questions
Lmna Priority (Leducq Foundation)'s website is http://lmna-priority.org
Lmna Priority (Leducq Foundation)'s LinkedIn profile is https://www.linkedin.com/company/priority-leducq
Lmna Priority (Leducq Foundation)'s industry is
Research Services
Lmna Priority (Leducq Foundation)'s top competitors are
Inthera,
Korea Institute For Advancement Of Technology (Kiat),
5th International Meeting On Laminopathies,
Khidi Usa,
Leducq Foundation For Cardiovascular Research,
Cardiovascular Research Institute Maastricht (Carim),
Orthopedie Umc Utrecht,
Bactivac,
Cancer Research Umc Utrecht,
Osong Medical Innovation Foundation.
Lmna Priority (Leducq Foundation)'s categories are Research Services
